Une publication apporte des informations supplémentaires sur le traitement de la drépanocytose d’Emmaus Life Sciences Inc. approuvé par la FDA.
Lire le communiqué completAbout myTomorrow
At myTomorrows, we believe that everyone should be able to access all suitable treatment options, whenever available, wherever they exist. Working together with medicine manufacturers to devise and execute strategies for early access, we strive to make it easier for doctors and their patients who ran out of viable treatment options to find, get information about and access to medicines in development. myTomorrows has developed a Knowledge Base to combine vast amounts of medical and clinical data to present an actionable overview of the full clinical development pipeline.